Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13365114 | 1.00 | PDE4B (0.72) | PDE4BSLC6A4SLC6A3SLC6A2PDE4A | |
| SCHEMBL193015 | 1.00 | PDE4B (0.72) | PDE4BSLC6A4SLC6A3SLC6A2PDE4A | |
| SCHEMBL193014 | 1.00 | PDE4B (0.72) | PDE4BSLC6A4SLC6A3SLC6A2PDE4A | |
| SCHEMBL4154880 | 0.90 | PDE4B (0.60) | PDE4BSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4000213 | 0.90 | PDE4B (0.60) | PDE4BSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL191321 | 0.88 | PDE4B (0.60) | PDE4BSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL191712 | 0.88 | PDE4B (0.60) | PDE4BSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4156154 | 0.88 | PDE4B (0.60) | PDE4BSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL13365112 | 0.88 | PDE4B (0.60) | PDE4BSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15397578 | 0.88 | PDE4B (0.60) | PDE4BSLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| EP-2336105-B9 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| EP-2336105-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8592454-B2 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | PDE4B 3147/4885SLC6A4 271/4885SLC6A3 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.